uniQure stock falls 5.57 percent as cash reaches USD 810.3 million

uniQure stock closed at USD 42.76 on Nasdaq on September 23, 2026, down 5.57 percent from the prior session and 40.2 percent below its 52-week high of USD 71.50. The biotechnology company is moving toward a regulatory decision point for AMT-130, its investigational Huntington's disease gene therapy.

AMT-130 reaches regulators

On September 2, 2026, uniQure submitted a Biologics License Application to the U.S. Food and Drug Administration for accelerated approval of AMT-130. The company also filed a Marketing Authorisation Application with the United Kingdom regulator, as the SEC filing confirms.

The applications rely on three-year Phase I/II data and an external control from the Enroll-HD natural history database. The company requested priority review, which would create a six-month FDA review cycle after the agency's 60-day filing review period, according to GlobeNewswire.

Revenue grows as losses widen

For the second quarter of 2026, revenue rose 11 percent year over year to USD 5.8 million, driven mainly by license revenue. The result missed the USD 7 million consensus estimate, while the loss of USD 1.22 per share was wider than the USD 0.81 consensus loss, Zacks reported.

Liquidity provides the financial counterweight. Cash, cash equivalents and investments stood at USD 810.3 million on June 30, 2026, compared with USD 586.6 million on March 31, 2026, and management expects the resources to fund operations into 2030.

Nasdaq price stays below high

At USD 42.76, the September 23, 2026 closing price sits well below the 52-week high of USD 71.50, while the market capitalization stood at USD 2,966,107,264. For investors, the next valuation test is whether AMT-130 data and regulatory progress can outweigh the company's quarterly loss profile.